Celltrion Pharm reported on the 15th that its first-quarter revenue increased by 16% compared to the same period last year, reaching 112.5 billion won, while operating profit soared 191% to 10.7 billion won. The operating profit margin for the first quarter rose by more than 5 percentage points to 9.5%.
The company noted that it achieved "the largest quarterly revenue in history," stating, "Despite the increase in workforce and research and development expenses, we expanded our profit margin through reduced commissions and in-house production."
The main businesses, chemical (synthetic pharmaceuticals) and biosimilars (replica of biopharmaceuticals), recorded growth rates of 27% and 14%, respectively, contributing to revenue growth. The chemical business generated approximately 51.6 billion won in sales, while the biosimilars business generated 20.8 billion won.
The main product for the chemical sector, the liver medication "Godeks," recorded approximately 10% growth compared to the same period last year, achieving 16.2 billion won. In the biosimilars sector, the autoimmune disorder treatment "Remsima SC," which changed its formulation from intravenous (IV) to subcutaneous (SC), grew by 8%, contributing to total sales of 9.2 billion won for the Remsima product line. In the oncology sector, "Herzuma" increased by 18% to about 5.7 billion won, while "Vegzelma" surged 164% to approximately 1.4 billion won.
In the contract manufacturing sector, the commercial production of autoimmune disorder therapies "Jimpenetra" (the U.S. product name for Remsima SC) and "Yuflyma" among pre-filled syringe (PFS) products has significantly increased, recording sales of 18.9 billion won, a growth of 37% compared to the same period last year. Celltrion Pharm plans to enhance product competitiveness and expand contract manufacturing to promote revenue growth, securing differentiated competitiveness through active research and development investment.